A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

Clinical Cancer Research

Volumn 21, Issue 23, 2015, Pages 5277-5285

  Pandit Taskar, Neeta ^a,b   O'Donoghue, Joseph A ^a   Durack, Jeremy C ^a   Lyashchenko, Serge K ^a   Cheal, Sarah M ^a   Beylergil, Volkan ^a   Lefkowitz, Robert A ^a,b   Carrasquillo, Jorge A ^a,b   Martinez, Danny F ^a   Fung, Alex Mak ^a   Solomon, Stephen B ^a,b   Gönen, Mithat ^a   Heller, Glenn ^a   Loda, Massimo ^c   Nanus, David M ^b   Tagawa, Scott T ^b   Feldman, Jarett L ^a   Osborne, Joseph R ^a,b   Lewis, Jason S ^a,b   Reuter, Victor E ^a   Weber, Wolfgang A ^a,b   Bander, Neil H ^a,b   Scher, Howard I ^a,b   Larson, Steven M ^a,b   Morris, Michael J ^a,b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRACER; UNCLASSIFIED DRUG; ZIRCONIUM DEFEROXAMINE MONOCLONAL ANTIBODY J591 ZR 89; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; HUMAN TISSUE; IMMUNOSCINTIGRAPHY; INTERMETHOD COMPARISON; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOFT TISSUE METASTASIS; TUMOR BIOPSY; BONE NEOPLASMS; CLINICAL TRIAL; METASTASIS; MOLECULAR IMAGING; PROCEDURES; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REPRODUCIBILITY; SECONDARY; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS;

BIOMARKERS, TUMOR; BONE NEOPLASMS; HUMANS; MALE; MOLECULAR IMAGING; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS;

EID: 84945484394     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0552     Document Type: Article

References (31)

1. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, et al. Baseline 18FFDGPET/CTparameters asimaging biomarkers of overall survival in castrateresistant metastatic prostate cancer. J Nucl Med 2013;54:1195-201.
2. Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, et al. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: Relative findings and response to therapy. Clin Nucl Med 2011;36:192-8.
3. Sengoku T, Matsumura K, UsamiM, Takahashi Y, Nakayama T. Diagnostic accuracy of FDG-PET cancer screening in asymptomatic individuals: Use of record linkage from the Osaka Cancer Registry. Int J Clin Oncol 2014 19:989-97.
4. Minamimoto R, Uemura H, Sano F, Terao H, Nagashima Y, Yamanaka S, et al. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med 2011;25:21-7.
5. Morris MJ, Akhurst T, Larson SM, Ditullio M, Chu E, Siedlecki K, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005;11:3210-6.
6. Meirelles GS, Schoder H, Ravizzini GC, Gonen M, Fox JJ, Humm J, et al. Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressingmetastatic prostate cancer. Clin Cancer Res 2010;16:6093-9.
7. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998;83:2259-69.
8. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998;82: 2256-61.
9. McCarthyM, Siew T, Campbell A, Lenzo N, Spry N, Vivian J, et al. (1)(8)FFluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: Prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging 2011;38:14-22.
10. Ceci F, Castellucci P, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, et al. (11)C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. Eur J Nucl Med Mol Imaging 2014;41:878-86.
11. Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L, et al. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: Comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 2012; 39:13-26.
12. Rodari M, Lopci E, Pepe G, Antunovic L, Chiti A. [11C]-choline PET/CT in imaging locally advanced prostate cancer. Nucl Med Rev Cent East Eur 2011;14:118-9.
13. Haseebuddin M, Dehdashti F, Siegel BA, Liu J, Roth EB, Nepple KG, et al. 11C-acetate PET/CT before radical prostatectomy: Nodal staging and treatment failure prediction. J Nucl Med 2013;54:699-706.
14. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: A prospective study of 130 patients. Radiology 2010;254:925-33.
15. Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004;45:366-73.
16. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imagingwith a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41:11-20.
17. Hamilton A, King S, Liu H, Moy P, Bander N, Carr F. A novel humanised antibody against prostate specific membrane antigen (PSMA) for in vivo targeting and therapy. Proc Am Assoc Cancer Res Ann Mtg 1998; 39:440.
18. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003;170:1717-21.
19. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003;30:667-77.
20. Bander NH, Nanus D, Bremer S, Smith-Jones P, Kostakoglu L, Vallabhajosula S, et al. Phase 1 clinical trial targeting a monoclonal antibody (mAb) to the extracellular domain of prostate specific membrane antigen (PSMAext) in hormone-independent patients. J Urol 2000;163(4 Suppl): 160.
21. Pandit-Taskar N, O'Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, et al. Antibody mass escalation study in patients with castration-resistant prostate cancer using (111)In-J591: Lesion detectability and dosimetric projections for (90)Y Radioimmunotherapy. J Nucl Med 2008;49:1066-74.
22. Morris MJ, Pandit-Taskar N, Divgi CR, Bender S, O'Donoghue JA, Nacca A, et al. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res 2007;13:2707-13.
23. Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res 2005;11:7454-61.
24. Vallabhajosula S, Kostakoglu L, Hamacher KA, Brandman S, Bander NH, Goldsmith SJ. Pharmacokinetics, biodistribution and radiation dosimetry of radiolabeled anti-PSMA antibody: Comparison of In-111-DOTA-J591 with Lu-177-dota-J591. J Nucl Med 2003;44:322P-P.
25. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. Zr-89-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010;51:1293-300.
26. Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, et al. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41:2093-105.
27. Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 2010;5:739-43.
28. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007;25:540-7.
29. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigenmonoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22:2522-31.
30. Erdi YE. Limits of tumor detectability in nuclear medicine and PET. Mol Imaging Radionucl Ther 2012;21:23-8.
31. Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW,Bartlett DW, et al. Noninvasive imaging of PSMA in prostate tumorswith (89)Zr-labeled huJ591 engineered antibody fragments: The faster alternatives. Mol Pharmaceutics 2014;11:3965-73.